Sapient Capital LLC Has $1.25 Million Stock Position in Novo Nordisk A/S $NVO

Sapient Capital LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 66.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,114 shares of the company's stock after selling 36,184 shares during the period. Sapient Capital LLC's holdings in Novo Nordisk A/S were worth $1,250,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of NVO. Acadian Asset Management LLC raised its holdings in shares of Novo Nordisk A/S by 15,919.9% during the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock worth $72,523,000 after acquiring an additional 1,038,137 shares during the period. North Star Investment Management Corp. raised its stake in shares of Novo Nordisk A/S by 18.2% in the 1st quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock valued at $1,440,000 after purchasing an additional 3,200 shares during the period. Rhumbline Advisers raised its stake in shares of Novo Nordisk A/S by 10.2% in the 1st quarter. Rhumbline Advisers now owns 63,539 shares of the company's stock valued at $4,412,000 after purchasing an additional 5,898 shares during the period. Cim LLC raised its stake in shares of Novo Nordisk A/S by 4.0% in the 1st quarter. Cim LLC now owns 220,221 shares of the company's stock valued at $15,292,000 after purchasing an additional 8,398 shares during the period. Finally, Martin Capital Partners LLC raised its stake in shares of Novo Nordisk A/S by 261.5% in the 2nd quarter. Martin Capital Partners LLC now owns 76,448 shares of the company's stock valued at $5,276,000 after purchasing an additional 55,298 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.7%

Shares of NVO opened at $58.20 on Thursday. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $135.20. The firm has a market cap of $259.86 billion, a P/E ratio of 15.99, a price-to-earnings-growth ratio of 2.17 and a beta of 0.66. The firm's 50-day simple moving average is $57.21 and its 200 day simple moving average is $65.81. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is currently 22.53%.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent research reports. BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price on the stock in a research report on Wednesday, August 13th. TD Cowen lowered their price objective on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, August 19th. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. HSBC downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a report on Thursday, July 31st. Finally, UBS Group lowered shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.